Tutti gli studi
ReclutamentoConferma terapeutica (Fase III)Interventistico

A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus

This important study is looking into a new medicine, ganaxolone, for people experiencing a very serious and persistent type of seizure called refractory status epilepticus (RSE). RSE happens when seizures don't stop even after trying initial treatments. The main goal is to see if ganaxolone can stop these seizures within 30 minutes and prevent them from coming back for a certain period, without needing more treatment. Researchers will also be carefully checking for any side effects. This is a "Phase III" study, which means it’s one of the final steps before a medicine might be considered for wider use. Participants will be given either ganaxolone or a dummy medicine (a placebo) alongside their usual care, and neither they nor their doctors will know which one they are receiving.

A colpo d'occhio

Stato
Reclutamento
Fase
Conferma terapeutica (Fase III)
Sponsor
Marinus Pharmaceuticals Inc.
Obiettivo di iscrizione
66
Inizio
01 Set 2023

Di cosa tratta questo studio?

This study is about helping people who have a very serious type of seizure called refractory status epilepticus (RSE). RSE means that someone is having continuous seizures or seizures that keep happening one after another, and these seizures haven't stopped even after doctors have given them the usual first treatments.

The main aim of this study is to test a new medicine called ganaxolone. Doctors want to find out if adding ganaxolone to the treatments people are already receiving can stop these difficult-to-control seizures quickly and keep them from coming back. They also want to make sure the medicine is safe and doesn't cause too many unwanted side effects. Finding effective treatments for RSE is very important because it truly is a medical emergency.

To make sure the results are fair, some people in the study will receive ganaxolone, while others will receive a dummy medicine called a placebo. Neither the patients nor their doctors will know who is getting which, until the study is over. This is called a "double-blind" study and it helps researchers get the most accurate information about how well ganaxolone works compared to standard care alone. This is a "Phase III" study, which is usually the last big step before a new medicine can be considered for approval.

Punti chiave

  • This study is for adults with severe, ongoing seizures (refractory status epilepticus).
  • It's testing a new medicine called ganaxolone, given alongside usual care.
  • The main goal is to see if ganaxolone can quickly stop seizures and keep them from returning.
  • Half of participants will get ganaxolone, half will get a dummy medicine (placebo).
  • Safety is a top priority, and you'll be closely monitored for any side effects.
  • La partecipazione è volontaria e puoi ritirarti in qualsiasi momento.

Chi può essere idoneo?

This study is for adults, aged 18 and over, who are experiencing refractory status epilepticus (RSE). This means their seizures have continued despite receiving initial treatments from the doctors.

There are other specific medical conditions and treatments that might mean someone can't join the study, but these details are usually discussed directly with the study doctor.

Generally, if you are an adult and are currently experiencing seizures that haven't responded to standard treatments, you might be considered for this study.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Hai 18 anni o più?
  2. Are you currently experiencing seizures that haven't stopped with usual initial treatments?
  3. Are you able to receive medicines through a drip into your arm?
  4. Have your doctors advised that you have refractory status epilepticus (RSE)?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you are eligible and agree to take part, you will be given either the study medicine, ganaxolone, or a dummy medicine (placebo) through a drip into your arm, in addition to your usual care. Neither you nor your doctors will know which one you are receiving.

Throughout the study, the medical team will carefully monitor your seizures, your general health, and look for any side effects. They'll regularly check your level of consciousness and how well you are responding. You will have assessments at different times, including 24, 36, and 72 hours after starting the medicine, and again when you leave the hospital or at your final check-up.

The total time you spend actively monitored in the hospital for the study will depend on how you respond to treatment, but the main observations for stopping seizures are made within the first few days. The total duration of your participation in the study from start to final follow-up will be discussed by your doctor.

Rischi e benefici potenziali

Taking part in any medical study has potential benefits and risks. A potential benefit of this study is that ganaxolone might help stop your difficult-to-treat seizures when other medicines haven't. However, as with all medicines, ganaxolone could cause side effects. These could be mild or, in rare cases, more serious. The researchers will carefully monitor you for any problems. You will be given full details of known side effects before deciding to take part. Remember, you can choose to leave the study at any time, for any reason, without it affecting your medical care.

Locations (14)

Alcune posizioni dei siti sono approssimative. Stiamo migliorando questo — si prega di verificare con il team di prova prima di viaggiare.
  • —
    Non verificato
    Austria
  • —
    Non verificato
    Danimarca
  • —
    Non verificato
    Francia
  • —
    Non verificato
    Lituania
  • —
    Non verificato
    Germania
  • —
    Non verificato
    Finlandia
  • —
    Non verificato
    Ungheria
  • —
    Non verificato
    Italia
  • —
    Non verificato
    Croazia
  • —
    Non verificato
    Spagna
  • —
    Non verificato
    Belgio
  • —
    Non verificato
    Repubblica Ceca

Domande comuni

What is 'refractory status epilepticus'?

It's a serious medical emergency where seizures continue for a long time or keep happening without stopping, even after initial treatments.

What is ganaxolone?

It's a new medicine being tested to see if it can help stop these difficult-to-treat seizures.

Cosa significa 'doppio cieco'?

It means neither you nor your doctor will know if you're getting the study medicine or a dummy medicine, to keep the study fair.

Will I still receive my usual epilepsy treatment?

Yes, ganaxolone or the dummy medicine will be given in addition to the standard care you are already receiving.

Quanto durerà lo studio per me?

The main part of monitoring is in the first few days, and your overall participation will be discussed by your doctor, depending on how you respond.

Come saperne di più

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "A double-blind, randomized, placebo-controlled study to eval…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.